The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
≥18 years of age
Physician-reported diagnosis of moderate to severe plaque psoriasis
Be newly initiating deucravacitinib
Do not object to participate
Currently participating in or planning to participate in an interventional clinical trial
Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
Adult patients who have been diagnosed with moderate-to-severe plaque psoriasis and who intend to start deucravacitinib treatment in France
Cohort
Prospective
Deucravacitinib
DrugAs prescribed by treating clinician
Physician's Global Assessment (PGA) 0/1 response
Dermatology Life Quality Index (DLQI) 0/1 response
Time from date of treatment initiation to date of discontinuation
Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue
Click on the lead sponsor to view all of their trials.
